The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
Acute therapies continue to report strong growth compared to chronic ones.
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Subscribe To Our Newsletter & Stay Updated
